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Abstract
Objectives
We extend the method of Significant Zero Crossings of Derivatives (SiZer) to address
within-subject correlations of repeatedly collected longitudinal biomarker data and the
computational aspects of the methodology when analyzing massive biomarker databases.
SiZer is a powerful visualization tool for exploring structures in curves by mapping areas
where the first derivative is increasing, decreasing or does not change (plateau) thus explor-
ing changes and normalization of biomarkers in the presence of therapy.
Methods
We propose a penalized spline SiZer (PS-SiZer) which can be expressed as a linear mixed
model of the longitudinal biomarker process to account for irregularly collected data and within-
subject correlations. Through simulations we show how sensitive PS-SiZer is in detecting
existing features in longitudinal data versus existing versions of SiZer. In a real-world data anal-
ysis PS-SiZer maps are used to map areas where the first derivative of weight change after
antiretroviral therapy (ART) start is significantly increasing, decreasing or does not change,
thus exploring the durability of weight increase after the start of therapy. We use weight data
repeatedly collected from persons living with HIV initiating ART in five regions in the Interna-
tional Epidemiologic Databases to Evaluate AIDS (IeDEA) worldwide collaboration and com-
pare the durability of weight gain between ART regimens containing and not containing the
drug stavudine (d4T), which has been associated with shorter durability of weight gain.
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Results
Through simulations we show that the PS-SiZer is more accurate in detecting relevant fea-
tures in longitudinal data than existing SiZer variants such as the local linear smoother (LL)
SiZer and the SiZer with smoothing splines (SS-SiZer). In the illustration we include data
from 185,010 persons living with HIV who started ART with a d4T (53.1%) versus non-d4T
(46.9%) containing regimen. The largest difference in durability of weight gain identified by
the SiZer maps was observed in Southern Africa where weight gain in patients treated with
d4T-containing regimens lasted 59.9 weeks compared to 133.8 weeks for those with non-
d4T-containing regimens. In the other regions, persons receiving d4T-containing regimens
experienced weight gains lasting 38–62 weeks versus 55–93 weeks in those receiving non-
d4T-based regimens.
Discussion
PS-SiZer, a SiZer variant, can handle irregularly collected longitudinal data and within-sub-
ject correlations and is sensitive in detecting even subtle features in biomarker curves.
Introduction
In the study of changes in longitudinal biomarkers in response to therapy or disease progres-
sion, it is useful to be able to identify the periods in time where changes occur. A key challenge
arising from this effort is to isolate the underlying features of interest (say marker decreases or
increases) in the presence of potentially large data variation. For example, in a data set of
weight measurements in HIV-infected individuals initiating antiretroviral therapy (ART),
which forms the core illustration of our methods in this paper, a scatterplot involving a mere
1% of the data (Fig 1 top left panel) is largely indecipherable. The situation does not improve
when a “spaghetti” plot is generated (Fig 1, top right panel). However, a plot of the median
weight at binned time points (Fig 1, bottom left panel) starts picking up the rapid early weight
gains following ART initiation, but is less informative about the time when these gains reach a
plateau and the possibility of long-term weight decreases possibly resulting from treatment
toxicity or treatment failure.
The bottom right panel in Fig 1 includes three smooth weight trajectories at different values
of a smoothing parameter estimated via a penalized spline regression method (see Ruppert
et al., [1]), which appear to capture the well-known features in such data involving rapid
weight increase and subsequent plateau [2]. However, it is unclear what the durability of
weight gain is or whether there are decreases in weight after long-term exposure to therapy. In
addition, each smoothing level produces a slightly different fit, particularly with respect to the
timing of reaching the plateau in weight gain. As noted in Marron and Zhang [3], a hurdle in
the application of smoothing methods is the selection of the smoothing parameter, because
interesting features that are present in the data may be visible after applying some smoothing
techniques or at some levels of smoothing but disappear in others, so choosing among the vari-
ous smoothing techniques or the level of smoothing can be critical in extracting relevant fea-
tures from the data; and of course, there is a tremendous computational burden associated
with such data analyses, as the above conclusions were drawn from only about 1% of the
underlying database.
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The Significant Zero Crossings of Derivatives (SiZer) [4] was proposed to address many of
the aforementioned issues [5]. It is a useful Exploratory Data Analysis tool for understanding
the significant features resulting from smoothed curves. SiZer simultaneously studies a family
of smooth curves under a wide range of smoothing parameters (bandwidths) and produces
inference on a smoothed version of the underlying curve viewed at varying levels of smooth-
ing. The standard implementation of SiZer [5] is based on the local linear smoother with a
Fig 1. Four different visualizations of weight changes t (kg) after antiretroviral therapy initiation in involving data from 1% of HIV-infected patients
from the IeDEA database (2,000 patients, 46,207 observations). The upper-left panel (a) represents a scatter plot; the upper-right panel (b) shows a spaghetti
plot; the lower-left panel includes a plot of the mean weight over time; Lower-right panel represents smooth curves estimated at 3 different smoothing
parameter values.
https://doi.org/10.1371/journal.pone.0220165.g001
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kernel-type smoothing method for a single predictor and a single outcome data [6]. The SiZer
map graphically explores structures in curves under study by mapping areas where the curve is
significantly increasing, decreasing or does not change by studying its first derivative. Statisti-
cal inference is based on the derivatives of the smoothed curve by constructing confidence
intervals at each location and also at each level of the smoothing parameters. The technique
assembles these analyses at a wide range of smoothing parameters and synthesizes them in a
single “map” where increase, decrease and plateau regions are identified by different colors,
presenting an attractive global visualization of the data under many smoothing scenarios.
A number of extensions of the SiZer methodology have been proposed to increase inference
precision [7, 8]. Of greater relevance to this paper is the extension proposed by Park and col-
leagues [9], which relaxes the assumption of independent errors, thus ignoring spurious fea-
tures which are caused by the existence of dependence in the data. These and other authors
further extended the SiZer method into the area of time series [10, 11]. Another relevant exten-
sion is the SiZer for Smoothing Splines (SS-SiZer) [3], which uses splines to enhance detection
of true features in the data.
Despite its attractiveness as a data visualization tool, the SiZer map has not been used
widely in biological applications. This is unfortunate, since biological processes frequently
involve changes in various measures (most notably biomarkers), which evolve over time, in
response to disease progression or initiation and/or modification of clinical therapies. One
important reason for this is the fact that the SiZer and its extensions do not account for
within-subject correlation. This frequently arises in longitudinal settings from measurements
obtained repeatedly on the same individuals. A further technical complication is that the tim-
ing of these measurements becomes increasingly less regular with the passing of time (as sub-
jects miss or reschedule clinical visits). It should be clear that this is a much different problem
from time-series analysis, since longitudinal data are obtained from the same sample of study
subjects repeatedly over time. Thus, neither the originally proposed method of SiZer nor its
extensions in the area of time series fully address the challenges posed by longitudinal data.
It is a core aim of this paper to extend the method of SiZer maps to account for within-sub-
ject correlation in the setting of irregularly collected longitudinal biomarker data, since SiZer
offers an appealing global data visualization technique which can be tremendously useful in
answering many important biological questions about the evolution of these data over time.
We accomplish this by proposing a semiparametric extension of the SiZer methodology,
named Penalized Spline SiZer (PS-SiZer), which combines a penalized spline regression model
[10] with an embedded linear mixed-model representation of the marker evolution, coupled
with methods which increase the computational efficiency of the standard SiZer. These
computational advances are particularly attractive when analyzing massive databases with
hundreds of thousands of patients and millions of observations.
The paper is organized as follows: In the Methods we give a brief overview of the core ideas
of the SiZer methodology as originally proposed [1, 5] along with the SS-SiZer methodology of
Marron and Zhang [3] and present the proposed penalized spline PS-SiZer procedure for lon-
gitudinal data. Two simulation studies are presented in the Results where the proposed meth-
odology is compared with the local linear smoother LL-SiZEr [1, 5] and the SS-SiZer [3] in,
respectively, detecting changes and plateaus in longitudinal biomarker data. These are fol-
lowed by the analysis of a large database obtained from hundreds of thousands of HIV-infected
patients enrolled in care and treatment programs around the world participating in the Inter-
national Epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration, where body
weight measurements were collected repeatedly at each clinic visit. The clinical interest of this
analysis is to describe the pattern of body weight changes after initiation of antiretroviral ther-
apy as a surrogate of treatment effectiveness and to determine the durability of weight gain by
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detecting a plateau in weight increases and the presence of possible decreases after long-term
exposure to various therapeutic modalities. We conclude the paper with a brief discussion of
our findings.
Methods
SiZer
More formally, for a given set of observed data ðXi;YiÞ
n
i¼1
� �
and a smoothing function g(x), we
can consider a non-parametric regression model as follows:
yi ¼ gðxiÞ þ �i; i ¼ 1; . . . n; �ieNð0; s
2
εÞ ð1Þ
Here, g(x) is some “smooth” regression function that needs to be estimated from the data and
�i is the random error component with variance s
2
ε. The smooth function g(x) may be a non-
parametric regression function indexed by a smoothing parameter λ (bandwidth) as gλ(x) [1].
Local linear smoother SiZer: LL-SiZer
The LL-SiZer model specification [5] considers a family of smooth functions indexed by the
smoothing parameter l : fg^ l xð Þ : l 2 lmin; lmax½ �g as in Ruppert, Wand and Carroll [1]. A sig-
nificant feature in the data is detected from the confidence limits of the first derivatives of the
fitted model g^ l at each level of λ.
The LL-SiZer applies the local linear regression method of Fan and Gijbels [12] to estimate
gλ(x) and its derivative, g 0l xð Þ. A common estimate of gλ(x) at each location of x is given by the
equation
g^ l xð Þ ¼ argmin
Xn
i¼1
½yi   fa0 þ a1 xi   xð Þ�
2
� Kl x   xið Þ
where argmin is the minimum of the sum jointly over the regression coefficients, a0 and a1. A
line is fitted to the data for each x using Kλ-weighted least-squares, where K(�) is a Gaussian
kernel. A SiZer map is then constructed by changing the value of the smoothing parameterλ.
The estimated regression function of gλ(x), and g 0l xð Þ are obtained to construct a family of
smooth functions at various levels of the smoothing parameter. Confidence limits for g 0
^
l xð Þ
are obtained as
g^ 0
l
xð Þ � ql � s^dðg^
0
l
xð ÞÞg
where qλ is a suitably defined Gaussian quantile [7]. In the SiZer map, a pixel at x and a specific
smoothing level λ is colored blue if the confidence interval suggests that g 0 xð Þ > 0 (implying
that the curve at x is increasing, red if the confidence interval suggests that g^ 0
l
xð Þ < 0 (implying
that the underlying curve is decreasing) and purple if the confidence interval contains zero
(implying that no significant change in the curve can be detected).
SiZer for smoothing splines (SS-SiZer)
The SiZer for Smoothing Splines (SS-SiZer) [3] is an extension of a kernel-type estimation to
the smoothing spline estimation. SS-SiZer incorporates the smoothing spline model and esti-
mates the regression function by minimizing
yi   gl xið Þ½ �
2
þ l
Z
g@
l
xð Þ
� �2dx
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where λ is the smoothing spline parameter that determines the smoothness of the regression
estimate g^l xð Þ and
R
g@
l
xð Þ
� �2dx represents the roughness of the underlying function gλ(x).
Here, the smoothing spline function gλ(x) is a natural cubic spline with knots at data locations
x1 . . . xn. The smoothing parameter, λ acts similarly as the bandwidth in the LL-SiZer presented
in the previous section.
SS-SiZer constructs point-wise confidence limits to produce the map. In our research, we
apply the simultaneous confidence limit to the SS-SiZer model to address the multiplicity com-
parison issue (see next section). Otherwise, the interpretation remains the same as in the SS-Si-
Zer maps [3]. For other implementation details, such as the expression of first derivative
estimate and its standard error, the reader is referred to the paper by Marron and Zhang [3].
The penalized SiZer (PS-SiZer)
In this section, we present our extension of the SiZer map to handle data that arise in the longi-
tudinal setting. In the proposed model, we consider subject-specific correlation arising from
data obtained repeatedly on the same individuals. We utilize an approach similar to the stan-
dard SiZer in which a family of smooth functions is used at various levels of smoothing param-
eters λ. We enhance the underlying model through the use of a computationally efficient
smoothing model (presented below). In the PS-SiZer map, we also apply simultaneous confi-
dence limits to resolve the issues related to multiple comparisons. Our proposed methodology
extends SiZer in the following areas:
1. Adding a random intercept component to summarize subject-specific correlation
2. Applying a P-spline [13] as the underlying smoothing function
3. Constructing a simultaneous 95% confidence limit addressing multiple-comparison issues
Model specification
Let yij denote measurements on subject i = 1, 2, . . . n at time xij, j = 1,2. . .ni. We model the
responses as,
yij ¼ glðxijÞ þ bi þ εij; εij eNð0; s
2
εÞ ð2Þ
where gλ(xij) is a smooth function indexed by a smoothing parameter λ and εij is a vector of
random normal error terms with mean 0 and variance s2
�
. The model in (2) extends the basic
model in (1) by adding the random subject-specific component bieN 0; s
2
b
  �
, a normally dis-
tributed random intercept with mean 0 and variance s2b which accounts for the within-subject
correlation in the repeatedly collected measurements yij in subject i. As this model is a member
of the family of linear mixed models, a major advantage from its use is the ability to handle
longitudinal data at irregularly spaced time points [14]. In this paper we use the P-spline
model of Eilers & Marx [13], as the underlying smoothing method to estimate the function gλ.
The P-spline model specification includes B-splines as the bases functions with evenly spaced
knots with the difference penalty applied directly to the B-spline regression parameters to con-
trol the smoothness of the function gλ. Let Bm(xij;p) denote B-spline basis of degree p with k0
+ 1 internal knots. The number of B-splines is M = k0 + 1+p in the regression, resulting in the
following approximation of the smooth function gλ:
gl xij
� �
¼
XM
m¼1
amBmðxij; pÞ
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where am is a vector of coefficients, and Bm(xij;p) is the B-spline basis function of degree p. For
the penalty term, the P-spline model of Eilers and Marx uses a base penalty on higher-order
finite differences, Dd
T
Dd[13]. Consequently, the difference penalty matrix with order d can be
written as, aTDd
T
Dd a. Here, Δd is a matrix such that Δd constructs the vector of d
th difference
of the coefficients a i.e., Δam = am – am − 1; Δ2am − 2am − 1 + am − 2 and so on.
The second component of the model is the addition of a subject-specific random effect
bieN 0;s
2
b
  �
. This results in the penalized least square objective function minimizing
ky   Ba   Zbk2 þ laTDd
T
Ddaþ ðs
2
ε=s
2
bÞb
Tb ð3Þ
where Z ¼
11 � � � 0
..
. . .
. ..
.
0 � � � 1n
0
B
B
@
1
C
C
A and 1i ¼
1
..
.
1
2
6
6
4
3
7
7
5
nix1
Mixed model representation
The minimization problem discussed in the previous section can be handled using the mixed-
model framework [15]. Eq (3) can be turned into a regular mixed model by making use of the
mixed-effect model framework discussed in detail in [1, 16–18] among others. Let us first con-
sider the difference matrix, Δd that has dimension k0 þ 1þ pð Þ � ðk0 þ 1þ p   dÞ: The pen-
alty matrix D
T
dDd is singular and has rank ðk
0 þ 1þ p   dÞ. A singular value decomposition of
D
T
dDd leads to D
T
dDd ¼ Udiag Lð ÞU
T with U are the eigenvectors and L is the diagonal matrix
of eigenvalues in non-increasing order. Thus, k0 þ 1þ p   d eigenvalues are strictly positive
and the remaining d are zeros. Hence, U and Λ can be represented as U = [U+, U0] and Λ ¼
ðLT
þ
; 0T
þ
Þ
T
respectively. The dimension of U+ is now ðk0 þ 1þ pÞ � ðk0 þ 1þ p   dÞ with cor-
responding non-zero elements of vector L. Consequently, we can rewrite Ba as
Ba ¼ BUUTa ¼ B U0U
T
0
aþ Uþdiag L
  1
2
þ
� �
diag L
1
2
þ
� �
UT
þ
a
h i
¼: B U0bþ Uþdiag L
  1
2
þ
� �
u
h i
¼: Xbþ ZBu
and
aTDTdDda ¼ a
TUdiag Lð ÞUTa ¼ aTU0diag 0q
� �
UT
0
aþ aTUþdiagðLþÞU
T
þ
a ¼ uTu
The mixed-model representation of the smooth function is Xbþ ZBu, where
ueN 0; s
2
uIkþ1þp  d
� �
. Our final model, including the random intercept, is of the form,
Y ¼ Xbþ ZBuþ bi þ ε ð4Þ
where ueN 0;s
2
uIkþ1þp  d
� �
; bieN 0; s
2
b
  �
and εeN 0;s
2
εIn
  �
.
The model in (4) above has three components. Xβ represents the fixed overall effect while
ZBu corresponds to the smoothing function and bi, subject-specific random intercept, mea-
sures the random departure of subject i from the overall effect. The estimates of the parameters
and the random coefficients are obtained as the best linear unbiased predictors (BLUP) from
the mixed model using the restricted maximum likelihood (REML) criterion for the variance
components. Eq (4) can thus be solved using any standard mixed-model software. We utilized
the R-package mgcv::gam [19], which provides a computationally feasible approach to the
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parameter estimation in Eq (4). We obtained the estimate of gλ(x), the mean population curve
at x, and the quantities of interest to generate the PS-SiZer map as the most crucial component
in the PS-SiZer map is to estimate the first derivatives of the fitted functions g^ l xð Þ(i.e. g^l 0 xð Þ
and the variance of g^l 0 xð Þ and associated confidence bands. The gam() function from the R
library mgcv was used to estimate the function g(x) at varying levels of the smoothing parame-
ter λ. The PS-SiZer map includes a number of levels of the smoothing parameters. In the pres-
ent application, we used a range between log10(λREML) ± 2, where λREML is the estimated
smoothing parameter obtained via the REML approach using mixed model representation of
the P-spline model. At each smoothing level, the resultant smoothing function component is
obtained and extracted from the subsequent model fitting.
Inference
In the previous sections the point estimate for the model parameters were discussed, yet we are
also interested in finding the confidence intervals for the quantities derived from them, such as
an estimate of smooth function, g^ l xð Þ and the first derivatives of the smooth function, g^l 0 xð Þ.
We describe the estimate of the covariance matrix for the smoothing parameters specified by
[18]. Let F ¼ bb
� �
contain all the fixed and random effects from the smooth term only and let
C ¼ X ZB�½ be the corresponding model matrix. Let Z be the random effect model matrix
excluding the columns corresponding to the smooth terms and s2b be the corresponding ran-
dom effect covariance. The covariance matrix is V ¼ Z s2bZ
T þ s2
�
I. Therefore, the estimated
covariance matrix (S) for the parameters is
S ¼ cov Fð Þ ¼ CTV   1C þ D˘
  �  1
where D˘ is the positive semi-definite matrix of the coefficients for the smooth terms. The stan-
dard error of the smooth function estimate, s^eðg^ l xð ÞÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
CxðSÞCTx
p
with Cx = [Xx ZBx].
Estimate and variability bands of the derivatives
The derivatives of the smooth function gλ(x) are obtained by defining C0x ¼ X0x Z
0
Bx½ �: Here,
X0x ¼
d
dx Xð Þ and Z
0
Bx ¼
d
dx Zxð Þ. The first derivative estimate of g^ l xð Þ is:
g^l
0 xð Þ ¼ C0xF
The estimated standard error of g^l 0 xð Þ is s^e g^l 0 xð Þð Þ ffi
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
C0xð
P
Þ�C
T
x
q
.
Confidence bands
The construction of the PS-SiZer map involves a family of smooth functions based on the con-
fidence bands of the derivatives g^l 0 xð Þ. We used 100 values of the smoothing parameter λ on
the logarithmic grid to construct the PS-SiZer map. The range of the smoothing parameters
λmin, λmax was chosen as,
ðlogðlminÞ; logSðlmaxÞÞ ¼ ½ðlog10 lREMLð Þ   2; log10 lREMLð Þ þ 2�
The number 2 above is arbitrary. However, the range of the smoothing parameters shown
above spans 4 orders of magnitude giving us a picture of the estimated function at a sufficient
smoothing span. We obtained the λREML from the REML estimate of the variance components
using the same P-spline methodology.
The PS-SiZer can be viewed as a collective summary of a large number of hypothesis tests
so multiple-testing issues must be addressed. We follow Ruppert et al., [1] who showed that
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the penalized spline has fairly straightforward simulation-based simultaneous confidence
bands which can be used in situations when multiplicity testing is carried out. Suppose we
want a simultaneous confidence band for gλ(�) on a grid of x-values, xgrid ¼ ðx1; � � � ; xrÞ and
define
glðxgridÞ ¼
glðx1Þ
..
.
glðxrÞ
2
6
6
4
3
7
7
5
A 100(1 – α)% simultaneous confidence band for gλ(xgrid) is
g^ l xgrid
� �
� ql 1   að Þ
SD^ fg^ l x1ð Þ   glðx1Þg
..
.
SD^ fg^
l
xrð Þ   glðxrÞg
2
6
6
6
4
3
7
7
7
5
where g^
l
ðxgridÞ is the corresponding empirical best linear unbiased predictor (EBLUP)
obtained from the mixed model framework. Here, qλ(1 – α) is the (1 – α) quantile of the ran-
dom variable at a smoothing level λ, i.e.,
supx2X j
g^ lðxÞ   glðxÞ
SD^ fg^ lðxÞ   glðxÞg
j ð5Þ
which is the supremum on the set fglðxgridÞ : x 2 Xg. The quantile qλ(1 – α) was approximated
using N = 10,000 simulations. The N simulated values were sorted from smallest to largest, and
the one with rank (1 – α)N was used as qλ(1 – α). For a PS-SiZer map, we obtained the 95%
quantile of Eq (4) based on a simulation of size N at each level of λ. The confidence limits for
g^ 0l xð Þ were obtained as follows:
g^ 0
l
ðxÞ � qlð1   aÞ� sd
^
ðg^ 0
l
ðxÞÞg ð6Þ
Results
Simulation studies
In practice, the fundamental function of a SiZer map is to detect the underlying features in the
data. For this reason, it is natural to compare the SiZer maps according to which ones detect
the correct number of underlying features.
We have conducted Monte Carlo simulation studies to evaluate the performance of PS-Si-
Zer map under various scenarios. The key objective of this simulation study was to compare
the PS-SiZer with the LL-SiZer and SS-SiZer. Our simulation studies were designed to mimic
the HIV data analyzed later as part of the illustration of the methodology. In doing so, we use
the concept of effective degrees of freedom (EDF) to encapsulate the complexity of the model as
the actual degrees of freedom are not defined for semiparametric models. We use the estab-
lished method for estimation of the EDF, i.e., the trace of the smoother matrix (see Hastie and
Tibshirani [20] as cited in Chauduri and Maron[5]).
Using these simulated data, the relative performance of the SiZer maps was evaluated by the
following approaches:
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1. By making the SiZer maps comparable at a similar level of Effective Degrees of Freedom.
For this reason all three SiZer maps (PS-SiZer with LL-SiZer and SS-SiZer) were generated
with the same range of EDF.
2. By comparing the performance of the three SiZer maps at various levels of EDF according
to which flags more features of a curve when a curve changes its status (increasing, decreas-
ing or stable) from one to another.
3. By comparing the performance of the three SiZer maps which are most sensitive to detect
plateaus that are really present in the data.
In this research, performance of the PS-SiZer maps are presented in two different simula-
tion studies: “Simulation Study 1” which addresses item 2 above and “Simulation Study 2”
which addresses item 3.
Simulation study 1. Longitudinal data were simulated as xi chosen to be equally spaced in
the interval [0, 1] with
f ðxijÞ ¼ 65þ 25e
  2:0�xij�sinð5pðxij þ 5ÞÞ þ bi þ εij
where εijeN 0; s2ε
  �
is random noise, bieN 0;s2b
  �
is the subject-specific random intercept and
xij denote the time of measurement. The function sin (5 π(x + 5)) is a periodic function which
has five features. By this term, we mean changes in the curve from increasing to decreasing or
vice versa. The quantity, 25e  2:0x is a function to control the spread of the periodic sine func-
tion, which has the effect of diminishing the size of the features at higher time intervals.
We compared three SiZer maps through the various levels of combination of error variance
and subject-specific variance, ðs2ε : s
2
bÞ ¼ 2 : 5ð Þ; 5 : 2ð Þ; and 5 : 15ð Þ respectively (Table 1).
For each scenario of different variance combination, 50 trials were generated consisting of
N = 100 subjects each and the number of observations per subject was ni = 10 for i = 1, . . .N.
For each simulated trial, three different SiZer maps were generated at 100 levels of EDF.
Table 1 represents the mean proportion of features detected by the 50 simulated data sets at
various levels of s2ε and s
2
b. All three maps detected the first three features in the data most of
the time. We were mainly interested to find how sensitive PS-SiZer is to detect the fourth and
the fifth features of the true curve compared to LL-SiZer and SS-SiZer, as these were signifi-
cantly diminished by the addition of the phasing-out component in the data as described
above. When subject-specific variation is small (i.e., s2b ¼ 2), PS-SiZer detected all five features
51% of the time, whereas the SS-SiZer and LL-SiZer were able to detect all features 2% and
14% of the time respectively. At the same variability level, four features were detected by
Table 1. Finding features: Simulation study-1 with varying variability.
SiZer Maps
Variability (σ2ε : σ
2
b) Number of features detected LL-SiZer SS-SiZer PS-SiZer
5.0: 2.0 Five 14% 2% 51%
Four 34% 47% 88%
2.0: 5.0 Five 4% 10% 30%
Four 32% 62% 85%
5.0: 15.0 Five 0% 5% 8%
Four 24% 40% 68%
Proportions are from 50 simulation data sets.
https://doi.org/10.1371/journal.pone.0220165.t001
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PS-SiZer 88% of the time, compared to 47% and 34% by SS-SiZer and LL-SiZer respectively.
When the subject-specific variation is high (i.e., s2b ¼ 15), PS-SiZer was still able to detect four
features in the data almost 68% of the time compared to 40% and 24% by SS-SiZer and LL-Si-
Zer respectively. Interestingly, the fifth feature was not detected by LL-SiZer at all in this vari-
ability level, compared to 8% by PS-SiZer and 5% by SS-SiZer (Table 1).
Results from the above table are illustrated in Fig 2. Three maps were generated for each of
the three methods under comparison from a randomly chosen trial from out of the 50 trials
generated in the simulation study s2ε : s
2
b
  �
¼ ð5 : 15Þ. In the Figure, the x-axis is represents
time and the y-axis the EDF or the scale of smoothing of the three maps. As it is clear from the
Figure, all three maps were able to clearly flag the dominant first and second features (blue and
then red regions in the maps). However, in the majority of smoothing levels, LL-SiZer could
Fig 2. Simulation study 1. Upper-left panel: True function; Upper-right panel: LL-SiZer map. Lower-left panel: SS-SiZer map.
Lower-right panel: PS-SiZer map. For the SiZer maps, vertical axis represents 100 levels of EDF and the horizontal axis represents
time.
https://doi.org/10.1371/journal.pone.0220165.g002
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not flag the third or fourth features as being statistically significant and did not detect the fifth
feature at any level of EDF as mentioned above in the description of Table 1. SS-SiZer detected
all four features for a large proportion of smoothing parameters and was able to detect the fifth
feature only at higher levels of EDF, i.e. undersmoothing. By contrast, PS-SiZer detected all
five features at the majority of smoothing parameter levels (Fig 2).
Simulation study 2. In this simulation study, our aim was to illustrate how sensitive
PS-SiZer map is compared to LL-SiZer and SS-SiZer in detecting the plateau of an increasing
function. The true curve and the first derivative of the curve are presented in the top left panel
of Fig 3. The data were generated as xi equally spaced in [1:20) with
f xij
� �
¼ 85  
xij
4
  e   xijþ4:5ð Þ þ bi þ εij
where xij are time measurements as before, εijeN 0; s2εI
  �
is independent random noise and
bieN 0;s2b
  �
is the subject-specific random intercept. In a manner similar to Simulation Study
1, we generated 50 simulated trials, each with N = 100 subjects and involving ni = 10 equally
spaced time points i = 1, . . ., N. We consider an error variance s2ε ¼ 10 and a subject-specific
random variation s2b ¼ 5. For each simulated trial, three SiZer maps were generated at 100 lev-
els of EDFs.
The function used in this example had a true plateau at time x ¼ 4:5þ ln 1
4
  �
e5:89. The
sensitivity of the SiZer maps was calculated at each level of EDF by following exploring at
which point in all three SiZer maps, a blue region changed to a purple region at each level of
EDF. The process was repeated for 50 simulation trials. The summary of the first time point
where the plateau was detected by the three SiZer maps is presented as a box plot (Fig 4).
The box plot summary shows that the PS-SiZer map detects the earliest time point of the
plateau at x ~ 5.89 the closest estimate of the true value. By contrast, LL-SiZer and SS-SiZer
detected the plateau of the curve at x> 6. The true data curve and the resulting three SiZer
maps from a randomly selected simulated trial are presented in Fig 3. Three maps were able
to plot the pattern of the curve by moving from the blue region to the purple region at all
levels of EDF.
Combined, Simulation Studies 1 and 2 demonstrate that the PS-SiZer map not only detects
the significant changes of the true curve, but is also sensitive enough to detect the true time
point where the curve reaches its plateau. Even though all three SiZer maps were able to detect
the dominant features of the underlying curves, (that is, the trajectory of the curve from signifi-
cantly increasing–blue area–to decreasing–red area–to non-significant–purple area), they
were not able to detect less pronounced features at almost all levels of the EDF and were less
sensitive than PS-SiZer in locating the true plateau of the curve.
Illustration
As an illustration of the proposed methodology of the PS-SiZer, we analyze data on weight
changes in people living with HIV who initiate ART. In addition to detecting features in the
data corresponding to body weight increases after the start of therapy, an important clinical
question pertains to the durability of weight gains under different treatment regimens. More
specifically, we explore possible differences in the durability of weight gain between stavudine
(d4T) containing ART regimens versus non-d4T-containing regimens. Previous literature sug-
gests that d4T is associated with lipodystrohy, a problem with the way the body produces and
stores fat [21] and long-term weight loss compared to other regimens such as, for example,
those containing Tenofovir [22] a regimen which is increasingly used as a first-line antiretrovi-
ral drug, particularly in the Southern Africa region.
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The present study includes data on 185,010 adults living with HIV from five regions within
the IeDEA collaboration [23]: Southern Africa (65.6% of the cohort), East Africa (21.9%),
West Africa (8.3%), Central Africa (3.2%) and Asia Pacific (0.9%). Baseline demographic data
of IeDEA patients identified by region and by d4t-containing versus non-d4T-containing regi-
men are shown in Table 2. In the sequel, we present in detail results from the Southern Africa
Fig 3. Simulation study 2. Upper-left panel: True function and first derivative; Upper-right panel: LL-SiZer map; Lower-left panel: SS-SiZer map;
Lower-right panel: PS-SiZer map. The vertical axis represents the 100 levels of EDF and the horizontal axis represents the time.
https://doi.org/10.1371/journal.pone.0220165.g003
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IeDEA region. Results from the remaining four regions are presented in less detail and are left
for the supplementary material.
PS-SiZer Maps for the Southern IeDEA region were generated for each ART group, i.e.,
one map each for the groups of patients initiating ART with a regimen containing or not con-
taining d4T. To address the issue of durability of weight gain, we need to determine the first
time point (in weeks from start of ART) at which weight gain stops, i.e., the time when either
weight stops increasing or starts to decrease. The PS-SiZer map provides an overall visual
Fig 4. Boxplot-summary of three SiZer maps: Time to detect a true plateau in the data.
https://doi.org/10.1371/journal.pone.0220165.g004
Table 2. Summary of baseline characteristics-IeDEA study by d4T and non-d4T based regimen.
d4T Regimen Non-d4T regimen
N Age (years) Female (%) Baseline Body weight (kg) N Age (years) Female (%) Baseline Body weight (kg)
Overall 98160 36(30–42) 64152 (65) 55.0 (48–62) 86850 36 (30–42) 50682 (58) 55.0(49–62)
Asia Pacific 963 35(29–40) 410 (43) 51.0 (45–58) 751 34 (29–42) 181 (24) 57.7(50–56)
Central Africa 2839 37 (31–44) 2008 (70) 56.0 (49–65) 3045 37 (31–44) 2118 (51) 56.0 (50–65)
East Africa 30990 37 (31–43) 20017 (78) 54.0 (48–61) 9571 37 (31–43) 5758 (22) 55.0 (49–62)
Southern Africa 55192 35 (30–42) 36227 (49) 55.0 (48–62) 66295 35 (30–42) 38137 (51) 55.0 (49–62)
West Africa 8176 39 (32–42) 5490 (55) 55.0 (48–64) 7188 41 (37–42) 4488 (45) 57.0 (50–65)
Summaries are median (IQR) or n (%)
https://doi.org/10.1371/journal.pone.0220165.t002
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representation of the longitudinal weight change after the start of ART. However, to reach a
conclusion on the durability of weight increases after ART start, we need to decide on a single
optimum level of smoothing. Our algorithm does not depend on a specific smoothing tech-
nique. Here we have used a P-spline (13) PSR model for its computational efficiency and flexi-
bility for correlated data. In addition, we took advantage of re-expressing the PSR model as a
linear mixed effect model (1). The REML estimate of the mixed model is used to obtain the
optimum smoothing parameter.
Statistical analyses were performed using SAS Software 9.3 and R software (2.13.2). SAS
was used to create the analysis datasets for each of the five IeDEA regions. The user defined R-
functions and the R package SiZer [24] was used to generate LL-SiZer maps. To generate
SS-SiZer and PS-SiZer maps, user defined R-functions and the R package mgcv::gam [19]
was used.
The PS-SiZer map for the Southern-Africa region is presented in Fig 5. The corresponding
maps generated for each of the remaining four IeDEA regions are presented in S1–S4 Figs.
Each Figure is divided into four panels. The smoothed trajectories of weight after ART initia-
tion at the optimum level of smoothing for the two regimens and the smoothed first derivative
of the weight change over time is the two types of regimens are shown in the top row. The
PS-SiZer maps for d4T-containing and non-d4T-containing ART regimens are shown in the
top row. In each PS-SiZer map, the vertical axis represents the level of smoothing and the hori-
zontal axis the time in weeks since the start of ART as described in the Methods. For example,
for d4T-containing regimens, at a medium level of smoothing (0.5–1.0), body weight increases
for about 60 weeks, as reflected by the blue color on the left of the PS-SiZer map. The area to
the right of the blue region is colored purple, indicating that no more significant increases in
body weight are evident after about 60 weeks from the start of ART. There are red regions in
the map at most of the smoothing levels indicating possible weight decreases. Similarly, at very
high smoothing levels, (i.e., for values of the smoothing parameter λ> 1.0), the entire map is
blue, following purple and red indicating weight increases, then stable or decreasing for the
entire follow-up period. The PS-SiZer map of body-weight changes among individuals initiat-
ing ART with a non-d4T-containing regimen shows that, at lower smoothing levels, there are
some blue and purple areas suggesting an intermittent weight increase. Otherwise, the map
consists of mostly blue areas (indicating weight increases) for medium and higher levels of
smoothing for up to about 150 weeks after ART initiation. This indicates that patients starting
ART with a non-d4T-containing regimen experience sustained body-weight increases for a
period possibly double that of patients treated with d4T-containing regimens.
To reach a conclusion about the comparison of the durability of weight changes in the d4T-
containing versus not-containing ART regimens, we choose the PS-SiZer analysis (top-row of
the PS-SiZer map) at the optimum level of smoothing for the Southern Africa IeDEA region
(Fig 5). This analysis shows that weight in patients treated with d4T-containing ART regimens
increased rapidly after ART initiation and plateaued afterwards. Consulting the first derivative
(Fig 5 top-row right panel), we observed that the 95% CI of the curve includes zero after 59.9
weeks in the group of patients who received a d4T-containing regimen compared to 133.8
weeks for patients treated with non-d4T-containing regimens. A numerical summary of these
results is shown in the first row of Table 3.
Similar analyses are presented in S1–S4 Figs for the East-Africa, West Africa, Central-
Africa, and Asia-Pacific IeDEA regions respectively. The SiZer maps corresponding to the East
and West Africa regions are very similar. For d4T-containing regimens (panel a1 in S1 and S2
Figs), blue areas are followed by purple areas after about 50 weeks for most levels of smoothing,
indicating significantly increasing weight during this period. After this point, weight gain
diminishes. By contrast, the blue areas in the SiZer maps corresponding to the non-d4T-
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containing regimens (S1 and S2 Figs) extend past week 80, indicating that weight continues to
increase past 80 weeks after initiation of ART. Analyses at the optimum smoothing level pro-
duced the estimated curves of weight measurements are shown in S1 and S2 Figs and rows 2
and 3 in Table 3. For East Africa, results at the optimal smoothing levels showed that the
weight in patients treated with d4T-containing regimens did not significantly increase after
52.9 weeks compared to 84.9 weeks for patients treated with non-d4T-containing regimens.
Fig 5. Southern Africa: Plots of the weight change and its first derivative (top row) and PS-SiZer Maps (bottom row), for d4T-containing and
non-d4T-contiainging ART regimens (left and right column respectively).
https://doi.org/10.1371/journal.pone.0220165.g005
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For West Africa, the results are similar, with d4T-containing regimens estimated to weight
gain for 43.9 weeks versus 92.9 weeks for the non-d4T-containing regimens.
Results were similar in analyses from data in the Central-Africa and Asia-Pacific IeDEA
regions (S3 and S4 Figs respectively) but the differences between the two regimens were less
pronounced. Analyses of data from the Central Africa IeDEA region are shown in S3 Fig and
in row 4 of Table 3. The estimated duration of weight increases in the Central Africa region
was 61.9 weeks for d4T-containing ART regimens versus 60.9 weeks for non-d4T-containing
regimens.
Results from the analyses of data in the Asia Pacific IeDEA region are presented in Fig 3
and row 5 of Table 3 The estimated duration of weight gain in d4T-containing regimens was
38.9 weeks versus 54.9 weeks in non-d4T-containign regimens.
Discussion
This paper presents a significant extension of the SiZer methodology, the penalized SiZer or
PS-SiZer. Current SiZer methods, such as the standard LL-SiZer [5] and SS-SiZer [3] do not
account for the correlation induced by repeated measurements obtained on the same patient,
which invariably arise in longitudinal settings with particular frequency in biomarker data. In
addition, to developing a SiZer variant which can take into account within-subject correlation,
our efforts were also centered on developing computationally efficient methods to address
analyses involving massive databases from tens of thousands of subjects and millions of indi-
vidual measurements.
The fundamental motivation of the originally proposed SiZer map is to detect the underly-
ing features in the data and present a global visualization of changes in quantitative data for a
spectrum of smoothing levels. The key goal of this research is to show propose a SiZer variant
which can detect more real features in data in the context of data collected repeatedly from the
same subjects at irregular time points longitudinally. From the simulation results, it was evi-
dent that both the standard LL-SiZer formulation and the SS-SiZer method, while able to
detect large dominant features in the data, missed more subtle features, because neither
method appropriately addresses within-subject variability. This results in wider confidence
intervals and a diminished sensitivity when features in the data become attenuated (i.e.,
smaller changes from increases to decreases or vice versa).
Marron & Zhang [3] have also attempted to compare these two maps by carrying out a
number of simulations studies. The authors concluded that the original local linear version
(here, LL-SiZer) of the SiZer and the smoothing spline SiZer (here, SS-SiZer) often performed
similarly, without one method dominating the other in all cases. Similar findings were
observed in our own simulation studies. By contrast, the PS-SiZer maps identified more
underlying features in the simulation data than the other two SiZer map methods at a wide
Table 3. Estimated weeks at which HIV-patients experienced non-increasing weight.
Durability of weight gain
Weeks after ART start (95% confidence interval)
IeDEA Region d4T-based regimen Non-d4T regimen
Southern Africa 59.92 (57.56, 62.27) 133.82 (131.08, 136.56)
East Africa 52.92(50.76, 55.08) 84.88 (80.57, 89.19)
West Africa 43.94 (39.43, 48.45) 92.87 (86.59, 99.14)
Central Africa 61.92 (54.86, 68.98) 60.92 (53.23, 68.37)
Asia-Pacific 38.94 (34.45, 43.43) 54.92 (46.69, 63.15)
https://doi.org/10.1371/journal.pone.0220165.t003
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range of smoothing levels. In addition, both LL-SiZer and SS-SiZer detected a plateau in the
data later compared to the PS-SiZer map, which detected the plateau almost exactly at the true
time that it occurred in the simulated data. The simulation studies thus clearly demonstrate
that, at a wide range of smoothing levels, PS-SiZer was more sensitive to small features in the
data than the other two methods, presumably due to its improved ability to account for the
presence of correlation in the data. More recently, Chen & Wang[25] proposed a new method
for using the penalized spline approach for functional mixed effects models with varying coef-
ficients. Their focus is different from our approach, which is used for the discovery of features
in the underlying population regression function, by expanding the applicability of the SiZer
approach to longitudinal designs where the P-spline model of Eilers & Marx [13] is used to
estimate the population regression curve.
The main idea of SiZer maps is to detect significant changes in the data by mapping areas
where the 95% confidence intervals of the first derivative is significantly different from zero.
The combination of the penalized spline regression model with random intercepts in the
PS-SiZer map results in narrower confidence intervals, which, in turn, lead to more sensitive
detection of even less prominent features present in the data compared to standard SiZer
maps. In summary, PS-SiZer is a reasonably accurate addition to the family of SiZer map
methods particularly when analyzing data from longitudinal settings.
In the application of the PS-SiZer methodology, we analyzed a database involving more
than 185,000 adult HIV-infected patients and well over two million longitudinal weight mea-
surements. Our ability to handle such a large data set, underlines the computational advan-
tages of the proposed methodology. In addition to a global visualization of the data, the
PS-SiZer analysis produced meaningful clinical results by showing that the durability of weight
gain experienced by after starting ART with regimens containing d4T is likely significantly
shorter than among persons who start ART with regimens which do not contain d4T.
Specifically, within the Southern Africa region, weight increases in the former regimens
were observed to end after about 60 weeks from initiating of ART compared to almost 133
weeks (2.5 years) among patients who started ART with regimens not containing d4T. While
the clinical importance of this finding is less pronounced, given the almost universal phasing
out of stavudine as a first-line regimen, weight gain among people living with HIV is a relevant
topic, particularly with the wide adoption of integrase inhibitors and dolutegravir in particular,
as main line antiretroviral therapies, all of which are known to result in significant weight gain
in these patients [26–28].
These analyses underscore the power of the methodology to detect meaningful features in
the data and can address similar questions with other biomarkers, particularly in situations
where normalization of the marker is of significant clinical importance. For example, the dura-
bility of increases in CD4-positive T-lymphocytes after ART initiation [29] or normalization
of inflammatory factors [30] is of major clinical significance in the setting of antiviral treat-
ment of people living with HIV as are numerous other cases of biomarkers, where the timing
of normalization of the marker following initiation of therapy can be estimated by the PS-SiZer
based on repeatedly obtained measures obtained on the same subjects over time.
Supporting information
S1 Fig. East Africa: Plots of the weight change and its first derivative (top row) and PS-Si-
Zer maps (bottom row), for d4T-containing and non-d4T-contiainging ART regimens
(left and right column respectively).
(TIF)
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S2 Fig. West Africa: Plots of the weight change and its first derivative (top row) and PS-Si-
Zer maps (bottom row), for d4T-containing and non-d4T-contiainging ART regimens
(left and right column respectively).
(TIF)
S3 Fig. Central Africa: SiZer maps (top row) and plots of the weight change and its first
derivative (bottom row), for d4T containing and non-d4T-contiainging ART regimens
(left and right column respectively).
(TIF)
S4 Fig. Asia Pacific: Plots of the weight change and its first derivative (top row) and PS-Si-
Zer maps (bottom row), for d4T-containing and non-d4T-contiainging ART regimens
(left and right column respectively).
(TIF)
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